USFDA1 Apr 2025, 02:33 pm
US Cancer Patient Cured of Severe Infection with Wockhardt's Zaynich™
AI Summary
A 15-year-old US patient with Acute Myeloid Leukemia (AML) and a drug-resistant infection was successfully treated with Zaynich™ (Zidebactam/Cefepime, WCK 5222) under compassionate use. The patient had not responded to nine antibiotics over 45 days and was left with few treatment options. The infection, traced to the liver, was treated with Zaynich™ for 41 days, resulting in the successful resolution of the infection. This marks the third US patient to benefit from Zaynich™, demonstrating its potential in combating drug-resistant infections.
Key Highlights
- 15-year-old US patient with AML cured of severe, drug-resistant infection with Zaynich™
- Patient had not responded to nine antibiotics over 45 days
- Zaynich™ administered under compassionate use
- Third US patient to benefit from Zaynich™
- 51 patients with life-threatening Gram-negative infections have been successfully treated with Zidebactam/Cefepime